Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

Blanco F, Barreiro P, Ryan P, Vispo E, Martín-Carbonero L, Tuma P, Labarga P, Medrano J, González-Lahoz J, Soriano V.

J Viral Hepat. 2011 Jan;18(1):11-6. doi: 10.1111/j.1365-2893.2009.01261.x.

PMID:
20088890
2.

Severe liver disease associated with prolonged exposure to antiretroviral drugs.

Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, Rivas P, Barreiro P, Mura MS, Babudieri S, Garcia-Samaniego J, González-Lahoz J, Soriano V.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):177-82.

PMID:
16688096
3.

Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.

Loko MA, Bani-Sadr F, Winnock M, Lacombe K, Carrieri P, Neau D, Morlat P, Serfaty L, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group..

J Viral Hepat. 2011 Jul;18(7):e307-14. doi: 10.1111/j.1365-2893.2010.01417.x.

PMID:
21692942
4.

Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.

Barreiro P, Martín-Carbonero L, Núñez M, Rivas P, Morente A, Simarro N, Labarga P, González-Lahoz J, Soriano V.

Clin Infect Dis. 2006 Apr 1;42(7):1032-9.

PMID:
16511772
5.

Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.

Martin-Carbonero L, de Ledinghen V, Moreno A, Maida I, Foucher J, Barreiro P, Romero M, Satta G, Garcia-Samaniego J, Gonzalez-Lahoz J, Soriano V.

J Viral Hepat. 2009 Nov;16(11):790-5. doi: 10.1111/j.1365-2893.2009.01133.x.

PMID:
19413693
6.

Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.

Castellares C, Barreiro P, Martín-Carbonero L, Labarga P, Vispo ME, Casado R, Galindo L, García-Gascó P, García-Samaniego J, Soriano V.

J Viral Hepat. 2008 Mar;15(3):165-72. doi: 10.1111/j.1365-2893.2007.00903.x.

PMID:
18233989
7.

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.

Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J.

Hepatology. 2004 Feb;39(2):311-7.

PMID:
14767983
8.
9.

Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.

Raffi F, Reliquet V, Auger S, Besnier JM, Chennebault JM, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S.

AIDS. 1998 Oct 22;12(15):1999-2005.

PMID:
9814868
10.

Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.

Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, Pol S, Carrat F, Cacoub P; French National Agency for Research on AIDS.; Viral Hepatitis-HC02-Ribavic Study Team..

Clin Infect Dis. 2008 Mar 1;46(5):768-74. doi: 10.1086/527565.

PMID:
18248298
11.

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.

Macías J, Castellano V, Merchante N, Palacios RB, Mira JA, Sáez C, García-García JA, Lozano F, Gómez-Mateos JM, Pineda JA.

AIDS. 2004 Mar 26;18(5):767-74.

PMID:
15075511
12.

Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.

Halfon P, Pénaranda G, Carrat F, Bedossa P, Bourlière M, Ouzan D, Renou C, Tran A, Rosenthal E, Wartelle C, Delasalle P, Cacoub P.

Aliment Pharmacol Ther. 2009 Jul;30(1):61-70. doi: 10.1111/j.1365-2036.2009.03995.x.

13.

Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.

Sánchez-Conde M, Berenguer J, Miralles P, Alvarez F, Carlos Lopez J, Cosin J, Pilar C, Ramirez M, Gutierrez I, Alvarez E.

Clin Infect Dis. 2006 Sep 1;43(5):640-4.

PMID:
16886160
14.

Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.

Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.

Antivir Ther. 1998;3 Suppl 4:57-60.

PMID:
10723512
15.

Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.

Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R, Palella F.

Clin Infect Dis. 2008 Jul 15;47(2):250-7. doi: 10.1086/589294.

PMID:
18532884
16.

Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.

Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA.

Antivir Ther. 2006;11(7):839-46.

PMID:
17302246
17.

Nucleoside analogues and mitochondrial toxicity.

Fleischer R, Boxwell D, Sherman KE.

Clin Infect Dis. 2004 Apr 15;38(8):e79-80.

PMID:
15095236
18.

Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients.

Barreiro P, Labarga P, Martín-Carbonero L, Amor A, Ruiz-Sancho A, Castellares C, González-Lahoz J, Soriano V.

Antivir Ther. 2006;11(7):869-77.

PMID:
17302249
19.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.

PMID:
10983647
20.

The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.

Cotte L, Bénet T, Billioud C, Miailhes P, Scoazec JY, Ferry T, Brochier C, Boibieux A, Vanhems P, Chevallier M, Zoulim F.

J Hepatol. 2011 Mar;54(3):489-96. doi: 10.1016/j.jhep.2010.07.030.

PMID:
21056493

Supplemental Content

Support Center